CRISPR/Cas9 Off-Target Effects [Podcast] - BioTechniques

Solving the off-target effects of CRISPR/Cas9

Bioinformatics & Computational Biology

 

We spoke to Mark Behlke, the chief scientific officer of Integrated DNA Technologies (IA, USA), about the current limitations of CRISPR/Cas9 techniques and the potential of the novel HiFI Cas9 enzyme to resolve these limitations, as shown in a sickle cell disease-causing mutation.